193 related articles for article (PubMed ID: 19418558)
1. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma.
Nagata H; Hatano E; Tada M; Murata M; Kitamura K; Asechi H; Narita M; Yanagida A; Tamaki N; Yagi S; Ikai I; Matsuzaki K; Uemoto S
Hepatology; 2009 Jun; 49(6):1944-53. PubMed ID: 19418558
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.
Murata M; Matsuzaki K; Yoshida K; Sekimoto G; Tahashi Y; Mori S; Uemura Y; Sakaida N; Fujisawa J; Seki T; Kobayashi K; Yokote K; Koike K; Okazaki K
Hepatology; 2009 Apr; 49(4):1203-17. PubMed ID: 19263472
[TBL] [Abstract][Full Text] [Related]
3. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
[TBL] [Abstract][Full Text] [Related]
4. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
Matsuzaki K; Murata M; Yoshida K; Sekimoto G; Uemura Y; Sakaida N; Kaibori M; Kamiyama Y; Nishizawa M; Fujisawa J; Okazaki K; Seki T
Hepatology; 2007 Jul; 46(1):48-57. PubMed ID: 17596875
[TBL] [Abstract][Full Text] [Related]
5. Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis.
Matsuzaki K
Histol Histopathol; 2006 Jun; 21(6):645-62. PubMed ID: 16528675
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis.
Kawamata S; Matsuzaki K; Murata M; Seki T; Matsuoka K; Iwao Y; Hibi T; Okazaki K
Inflamm Bowel Dis; 2011 Mar; 17(3):683-95. PubMed ID: 20602465
[TBL] [Abstract][Full Text] [Related]
7. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma.
Wu YH; Ai X; Liu FY; Liang HF; Zhang BX; Chen XP
Mol Med Rep; 2016 Feb; 13(2):1345-52. PubMed ID: 26648552
[TBL] [Abstract][Full Text] [Related]
8. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer.
Matsuzaki K; Kitano C; Murata M; Sekimoto G; Yoshida K; Uemura Y; Seki T; Taketani S; Fujisawa J; Okazaki K
Cancer Res; 2009 Jul; 69(13):5321-30. PubMed ID: 19531654
[TBL] [Abstract][Full Text] [Related]
9. Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis.
Suwa K; Yamaguchi T; Yoshida K; Murata M; Ichimura M; Tsuneyama K; Seki T; Okazaki K
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991602
[TBL] [Abstract][Full Text] [Related]
10. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.
Murata M; Yoshida K; Yamaguchi T; Matsuzaki K
World J Gastroenterol; 2014 Nov; 20(41):15018-27. PubMed ID: 25386050
[TBL] [Abstract][Full Text] [Related]
11. Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocellular carcinoma progression via miR-145/miR-21 mediated Smad3 phosphorylation.
Wu C; Chen W; Fang M; Boye A; Tao X; Xu Y; Hou S; Yang Y
J Ethnopharmacol; 2019 Mar; 231():98-112. PubMed ID: 30412748
[TBL] [Abstract][Full Text] [Related]
12. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.
Deng YR; Yoshida K; Jin QL; Murata M; Yamaguchi T; Tsuneyama K; Moritoki Y; Niu JQ; Matsuzaki K; Lian ZX
Clin Exp Immunol; 2014 Apr; 176(1):102-11. PubMed ID: 24372395
[TBL] [Abstract][Full Text] [Related]
13. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z
Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881
[TBL] [Abstract][Full Text] [Related]
14. Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy.
Kim SH; Ahn S; Park CK
Hepatobiliary Pancreat Dis Int; 2012 Feb; 11(1):51-9. PubMed ID: 22251470
[TBL] [Abstract][Full Text] [Related]
15. Phospho-Smad3L promotes progression of hepatocellular carcinoma through decreasing miR-140-5p level and stimulating epithelial-mesenchymal transition.
Hu X; Han D; Wang Y; Gu J; Wang X; Jiang Y; Yang Y; Liu J
Dig Liver Dis; 2021 Oct; 53(10):1343-1351. PubMed ID: 33775574
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta during carcinogenesis: the shift from epithelial to mesenchymal signaling.
Matsuzaki K; Okazaki K
J Gastroenterol; 2006 Apr; 41(4):295-303. PubMed ID: 16741607
[TBL] [Abstract][Full Text] [Related]
17. Involvement of Smad3 phosphoisoform-mediated signaling in the development of colonic cancer in IL-10-deficient mice.
Hachimine D; Uchida K; Asada M; Nishio A; Kawamata S; Sekimoto G; Murata M; Yamagata H; Yoshida K; Mori S; Tahashi Y; Matsuzaki K; Okazaki K
Int J Oncol; 2008 Jun; 32(6):1221-6. PubMed ID: 18497983
[TBL] [Abstract][Full Text] [Related]
18. Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis.
Yamaguchi T; Yoshida K; Murata M; Suwa K; Tsuneyama K; Matsuzaki K; Naganuma M
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682957
[TBL] [Abstract][Full Text] [Related]
19. Aberrant Smad3 phosphoisoforms in cyst-lining epithelial cells in the
Hama T; Nakanishi K; Sato M; Mukaiyama H; Togawa H; Shima Y; Miyajima M; Nozu K; Nagao S; Takahashi H; Sako M; Iijima K; Yoshikawa N; Suzuki H
Am J Physiol Renal Physiol; 2017 Dec; 313(6):F1223-F1231. PubMed ID: 28877884
[TBL] [Abstract][Full Text] [Related]
20. Reversible Smad-dependent signaling between tumor suppression and oncogenesis.
Sekimoto G; Matsuzaki K; Yoshida K; Mori S; Murata M; Seki T; Matsui H; Fujisawa J; Okazaki K
Cancer Res; 2007 Jun; 67(11):5090-6. PubMed ID: 17545585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]